Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Dr Miron on the Characteristics of Intraductal Carcinoma of the Prostate

June 23rd 2023

Benjamin Miron, MD, discusses the rationale for investigating molecular alterations in patients with intraductal carcinoma of the prostate.

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC

June 20th 2023

The FDA has approved talazoparib (Talzenna) plus enzalutamide (Xtandi) for use in patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Dr Miron on Molecular Alterations in Intraductal Carcinoma of the Prostate

June 15th 2023

Benjamin Miron, MD, discusses findings and clinical implications from a study investigating molecular alterations in patients with intraductal carcinoma of the prostate.

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

Dr Goel on the Preliminary Efficacy of Tinengotinib Monotherapy in Advanced Solid Tumors

June 13th 2023

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPC

June 4th 2023

The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC

June 4th 2023

Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.

Subsequent Treatments Feasible After Radium-223 in mCRPC

June 3rd 2023

Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.

Talazoparib Plus Enzalutamide Has Manageble Toxicity With Dose Modifications, Supportive Care in mCRPC

June 3rd 2023

The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.

Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC

June 3rd 2023

Patients with nonmetastatic castration-resistant prostate cancer who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide.

Dr Sokolova on Talazoparib Plus Enzalutamide in mCRPC

June 1st 2023

Alexandra Sokolova, MD, discusses key findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer and unanswered questions regarding the use of PARP inhibitors plus androgen receptor inhibitors in patients with biomarker-negative disease.

EMA Committee Recommends Piflufolastat 18F PSMA PET Imaging Agent for Prostate Cancer

June 1st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of piflufolastat 18F, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, for use in prostate cancer detection.

Dr Wise on the Deciding Between Doublet and Triplet Regimens in Prostate Cancer

May 31st 2023

David R. Wise, MD, PhD, discusses considerations for the use of doublet or triplet regimens for the treatment of patients with prostate cancer.

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

May 31st 2023

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate Cancer

May 31st 2023

Benjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.

Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC

May 30th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

FDA Approves First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30th 2023

The FDA has approved flotufolastat F 18 injection (Posluma) for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen level.

Dr Wise on the Optimal Use of Treatment Intensification in mHSPC

May 25th 2023

David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.

IO Therapy in mCRPC and Clinical Pearls

May 24th 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.